Recent Research on Leukemia Has Revealed 85 Drug Candidates in Phase II or III Stage of Development and More Than 50 Companies Are Involved In the Development of These Drugs.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c43821) has announced the addition of Leukemia - A Therapeutic & Competitive Insight to their offering.

Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry.

This has now clearly changed with the launch of Novartis' Gleevec (imatinib mesylate) for chronic myeloid leukemia (CML), which is presenting the industry with proof that development within the leukemia market produces lucrative returns. Gleevec saw sales rise 32 percent to $2.2 billion during 2005. Consequently, the historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected.

Research and analysis highlights

In the report "Leukemia - A Therapeutic & Competitive Insight" The author does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide a insight and framework to understand the complex field of leukemia therapeutics. In this report, the author provides one of the most comprehensive coverage of the R&D trends to set the future leukemia marketplace. The author presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. The research has identified 85 drug candidates in phase II or III stage of development and more than 50 companies are involved in the development of these drugs. Among these drugs you can clearly see substantial progress while others have failed. There will be a more intense competition in several of the leukemic sub-markets and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report

Thorough examination of status and impact of several novel drugs in development

Discussion of the challenges in current and future treatment strategies

Anticancer pipeline of most companies in the field

Key reasons to read this report

* Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in leukemia R&D, and the results of clinical trials to date

* Gain insight into the current challenges and commercial opportunities associated with leukemia therapy

* More than 130 high quality references

Some of the drugs included in this analysis

AG-858, Alemtuzumab, AP23573, Atra, Avastin, BAY 43-9006, CEP-701, Ceplene, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Gemtuzumab, Genasense, Gvax, Imatinib, OSI-461, PKC412, PTK787, Rituximab, SU5416, Troxacitabine, Valspodar, VELCADE, Xcytrin and Zarnestra

Content Outline:

1 Executive Summary

2 Cancer Highlights

3 Methodology

4 Table of Contents

5 Introduction

6 Current Treatment Strategies

7 Progress in Current Treatment Strategies

8 Key Therapeutic Strategies for Future Therapies

9 Competitive Landscape in Drug Development: The Late Stage Pipeline

10 Current Drug Development: The Early Stage Pipeline

13 Drug Index

14 Company Index

4.1 List of Boxes

4.2 List of Tables

Some of the companies included in this analysis:

Amgen, Antigenics, Bayer, Bioenvision, Biogen Idec, BTG, Cell Genesys, Cephalon, Cyclacel Group (Cyclacel), Exelixis, Genta, GlaxoSmithKline, Johnson & Johnson, Millennium, Novartis, Pharmacyclics, PDL BioPharma, Schering-Plough, SuperGen, Vion Pharmaceuticals and Wyeth

For more information visit http://www.researchandmarkets.com/reports/c43821